Recap: ESSA Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
ESSA Pharma (NASDAQ:EPIX) reported Q4 earnings with an EPS of $-0.12, beating estimates by 42.86% against an expected $-0.21. However, revenue was down $0 from the same period last year. In the previous quarter, ESSA Pharma's EPS beat led to a 0.36% drop in share price the following day.
December 12, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ESSA Pharma reported a better-than-expected Q4 EPS, but with no change in revenue from the previous year. Historically, a past earnings beat resulted in a slight share price drop.
While ESSA Pharma's earnings beat is positive, the lack of revenue growth and historical share price drop post-earnings beat suggest a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100